EnGeneIC in the News
2023
December 7, 2023
November 26, 2023
November 8, 2023
EnGeneIC's advanced metastatic pancreatic ductal adenocarcinoma patient makes full recovery.
January 31, 2023
2021
September 07, 2021
March 26, 2021
EnGeneIC Announces Board Appointment - Professor Bryan Williams
Feb 23, 2021
Worldwide Business - kathy ireland interviews Jennifer MacDiarmid
2020
August 11, 2020
EnGeneIC Announces Board Appointment - Dr. Mark Levitt
June 01, 2020
Abstract accepted to the Annual Meeting of the American Society of Clinical Oncology 2020
March 16, 2020
February 12, 2020
2019
December 18, 2019
Winner in Drug Delivery Technology category by Fierce Innovation Awards – Life Sciences Edition 2019
August 8, 2019
May 9, 2019
2017
September 5, 2017
EnGeneIC Announces Publication in The Lancet Oncology of First Clinical Study Employing EDV™ Nanocell Platform to Enable microRNA Replacement Therapy
March 21, 2017
EnGeneIC Doses First Patient in U.S. Phase 1 Clinical Study of Targeted EDV™ Nanocells in Recurrent Glioblastoma Multiforme
March 2, 2017
EnGeneIC Receives FDA Orphan Drug Designation for Targeted EDV™ Nanocells to Treat Glioblastoma Multiforme
2016
October 9, 2016
EnGeneIC Enters Into Research Collaboration with Takeda to Develop EDV™-Based Immunomodulatory Therapies for Oncology
April 7, 2016
EnGeneIC Announces Publication of Late-Stage Canine Brain Cancer Study Results in PLOS ONE
April 6, 2016
EnGeneIC Ltd. to Present at BIO CEO & Investor Conference 2016.
March 10, 2016
EnGeneIC receives Science Meets Business Top 25 Australian R&D spin-off companies award.
January 25, 2016
EnGeneIC Ltd. Strengthens Board of Directors to Support U.S. Expansion
January 5, 2016
EnGeneIC Limited to Present at the 34th Annual J.P. Morgan Healthcare Conference
2015
November 11, 2015
EnGeneIC Ltd. to Present at the Stifel 2015 Healthcare Conference
October 15, 2015
EnGeneIC Ltd. to Present at The 14th Annual BIO Investor Forum
September 16, 2015
EnGeneIC Ltd. to Initiate U.S. Phase 1 Clinical Study Using Targeted EDV™ Nanocells to Treat Advanced Glioma Patients
August 19, 2015
EnGeneIC Initiates Phase 1 Tailored-EDV Clinical Study in Solid Tumors
August 6, 2015
Indian Link – In-gene-ious!
June 22, 2015
Sky News – Nanotech trial early success
April 16, 2015
Globe Newswire – Foundation for Sarcoidosis Research Announces First New York Fundraiser With Support of EnGeneIC
February 4, 2015
EnGeneIC to Present at BIO CEO & Investor Conference 2015
January 6, 2015
EnGeneIC Completes $10 Million Series B Financing Led by U.S. Institutional Investor
2014
November 10, 2014
EnGeneIC and Asbestos Diseases Research Institute Initiate MesomiR-1 Phase 1 Trial in Patients with Late Stage Mesothelioma
September 15, 2014
EnGeneIC Named a Recipient of the Cancer Institute NSW Premier’s Award for Excellence in Translational Cancer Research
August 11, 2014
EnGeneIC Receives Patent from the USPTO for EDV™ Nanocell Technology
June 24, 2014
EnGeneIC Unveils Clinical Development Strategy for EDV™ Nanocell Technology
2012
November 8, 2012
European CanCer Organisation – First trial in humans of “minicells”: a completely new way of delivering anti-cancer drugs
November 15, 2012
Cancer Discovery – “Minicells” Safely Deliver Targeted Drugs
August 15, 2012
Tenterfield Star – Upclose: Dr Jennifer MacDiarmid
May 8, 2012
Blue Mountains Gazette – Hitting cancer for six
April 26, 2012
Australian Financial Review – Unique technique brings pets back from death’s door
January 26, 2012
AusBiotech Update – A promise to a dying friend turns to a quest for a cure
2007
May 7, 2007
New Scientist – ‘Mini-cells’ could stop side-effects of chemotherapy
August 8, 2007
Australian Story – For the Holy Grail